COcoa Supplement and Multivitamin Outcomes Study: Effects on Falls and Physical Performance

NCT ID: NCT05232669

Last Updated: 2026-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

21442 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-15

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The COcoa Supplement and Multivitamin Outcomes Study (COSMOS; NCT02422745) is a randomized clinical trial of cocoa extract supplement (containing a total of 500 mg/d flavanols, including 80 mg. (-)-epicatechins), and a standard multivitamin supplement to reduce the risk of cardiovascular disease and cancer among men aged 60 years and older and women aged 65 years and older. This ancillary study is being conducted among participants in COSMOS and will examine whether the cocoa extract supplement or the multivitamin supplement improve musculoskeletal health and prevent falls and declining physical performance in the increasing number of older adults in the U.S. with potential for clinical and public health benefits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fall Physical Performance Fracture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cocoa extract + multivitamin

Group Type ACTIVE_COMPARATOR

Cocoa extract

Intervention Type DIETARY_SUPPLEMENT

2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Multivitamin

Intervention Type DIETARY_SUPPLEMENT

Multivitamin

Cocoa extract + multivitamin placebo

Group Type ACTIVE_COMPARATOR

Cocoa extract

Intervention Type DIETARY_SUPPLEMENT

2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Multivitamin placebo

Intervention Type DIETARY_SUPPLEMENT

Multivitamin placebo

Cocoa extract placebo + multivitamin

Group Type ACTIVE_COMPARATOR

Cocoa extract placebo

Intervention Type DIETARY_SUPPLEMENT

Cocoa extract placebo

Multivitamin

Intervention Type DIETARY_SUPPLEMENT

Multivitamin

Cocoa extract placebo + multivitamin placebo

Group Type PLACEBO_COMPARATOR

Cocoa extract placebo

Intervention Type DIETARY_SUPPLEMENT

Cocoa extract placebo

Multivitamin placebo

Intervention Type DIETARY_SUPPLEMENT

Multivitamin placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cocoa extract

2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Intervention Type DIETARY_SUPPLEMENT

Cocoa extract placebo

Cocoa extract placebo

Intervention Type DIETARY_SUPPLEMENT

Multivitamin

Multivitamin

Intervention Type DIETARY_SUPPLEMENT

Multivitamin placebo

Multivitamin placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants who reported an injurious fall resulting in healthcare utilization (visit to a healthcare provider or hospital)
2. Participants who reported recurrent falls (2 or more falls per year)
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brigham and Women's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Meryl LeBoff

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Meryl S LeBoff, MD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Carolyn Crandall, MD, MS

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

LeBoff MS, Chou SH, Ratliff KA, Cook NR, Clar A, Holman B, Copeland T, Smith DC, Rist PM, Manson JE, Sesso HD, Crandall CJ. Rationale and design of an ancillary study evaluating the effects of the cocoa flavanol and/or multivitamin interventions on falls and physical performance outcomes in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS). Contemp Clin Trials. 2023 Feb;125:107078. doi: 10.1016/j.cct.2023.107078. Epub 2023 Jan 6.

Reference Type BACKGROUND
PMID: 36621596 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.cosmostrial.org/

COSMOS Trial Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021A008958

Identifier Type: OTHER

Identifier Source: secondary_id

2021P003714

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.